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Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda
Based on Parasitological and Molecular Assays
Roland A. Cooper,a Melissa D. Conrad,b Quentin D. Watson,c Stephanie J. Huezo,a Harriet Ninsiima,d Patrick Tumwebaze,d
Samuel L. Nsobya,d Philip J. Rosenthalb
Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USAa; Department of Medicine, University of California, San
Francisco, California, USAb; Department of Integrative Biology, University of California, Berkeley, California, USAc; Infectious Diseases Research Collaboration, Kampala,
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We evaluated markers of artemisinin resistance in Plasmodium falciparum isolated in Kampala in 2014. By standard in vitro
assays, all isolates were highly sensitive to dihydroartemisinin (DHA). By the ring-stage survival assay, after a 6-h DHA pulse,
parasitemia was undetectable in 40 of 43 cultures at 72 h. Two of 53 isolates had nonsynonymous K13-propeller gene polymor-
phisms but did not have the mutations associated with resistance in Asia. Thus, we did not see evidence for artemisinin resis-
tance in Uganda.
Artemisinin-based combination therapy is now the standardfor treating P. falciparum malaria. However, this regimen is
threatened by resistance to artemisinins, which manifests as de-
layed clearance of parasitemia after therapy, in Southeast Asia (1,
2). Recently, resistance has been associated with increased para-
sitemia in culture, compared to that in sensitive parasites, 72 h
after a 6-h pulse with dihydroartemisinin (DHA) and has been
associated with polymorphisms in propeller-encoding domains of
the Plasmodium falciparum kelch (K13; UniProt number
PF3D7_1343700) gene (3–6). Although artemisinin resistance is
evident to date only in Southeast Asia, the bulk of P. falciparum
malaria occurs in sub-Saharan Africa. Clinical resistance has not
been noted in Africa, as rapid parasite clearance has been the rule
in many trials, including those in Uganda (7–9). In recent surveys
in Uganda (10) and other locations in Africa (11–15), K13-pro-
peller gene polymorphisms were identified, but these were not the
mutations clearly associated with artemisinin resistance in Asian
isolates. Results for a new correlate of artemisinin resistance, the
ex vivo ring-stage survival assay (RSA) (3), have not been reported
previously for P. falciparum isolates from Africa. We characterized
artemisinin sensitivity by this assay and assessed K13 polymor-
phisms in isolates from Uganda. Parasites were collected from
patients diagnosed with malaria from May to August 2014 at Mu-
lago Hospital, Kampala. Samples were delinked from patient in-
formation, so clinical data were unavailable. After malaria diag-
nosis, excess blood collected in a heparinized tube as part of
clinical care was promptly delivered to the laboratory. Giemsa-
stained thin smears were made, and samples containing only P.
falciparum isolates with parasitemia of 0.1% were placed in cul-
ture after washing of erythrocytes, as previously described (16);
blood was also spotted onto filter paper. Samples with parasitemia
of 1% were diluted with uninfected erythrocytes for a final par-
asitemia of 1%.
The susceptibility of fresh isolates to DHA and chloroquine
was assessed by a standard ex vivo histidine-rich protein 2-based
enzyme-linked immunosorbent microplate assay, as previously
described (17), except that drugs were freshly diluted from frozen
stocks prior to each assay. Results from single assays were fitted to
a variable-slope sigmoidal function using GraphPad Prism 6.0f to
generate 50% inhibitory concentrations (IC50s). All data were vi-
sually assessed for parasite growth above the background and in-
tegrity of curve fits.
Parasite susceptibility to DHA was also assessed using the new
ex vivo RSA (3). First, 20-l erythrocyte pellets were added to 1.0
ml RPMI 1640 medium supplemented with 25 mM HEPES, 0.2%
NaHCO3, 0.1 mM hypoxanthine, 100 g/ml gentamicin, and
0.5% Albumax I (Invitrogen) containing 700 nM DHA or, for
controls, 0.1% dimethyl sulfoxide (DMSO) at a hematocrit of 2%.
Cultures were incubated at 37°C under 3% O2, 5% CO2, and 92%
N2 and, after 6 h, washed 3 times with 10 ml RPMI prewarmed to
37°C; then, they were placed in drug-free culture medium. At 72 h
after assay initiation, Giemsa-stained thin smears were prepared.
Cultures were considered viable and appropriate for assessment if
control parasitemia increased since the culture initiation. Para-
sitemias in the control cultures were determined by counting par-
asites per 1,000 to 2,000 erythrocytes. In DHA-pulsed cultures,
10,000 to 20,000 cells were scanned for parasites. RSA survival
rates were expressed as the proportion of parasites in the DHA-
treated cultures relative to controls at the end of the 72-h assay.
For some samples, cultures were maintained for up to 4 weeks
after initiation of the experiment, with smears assessed on alter-
nating days. For positive cultures, blood spots were collected on
filter paper.
DNA was extracted from filter paper blood spots using Chelex-
100, and gene fragments spanning loci of interest were amplified
by nested PCR (10, 18). K13-propeller-encoding domains
(codons 440 to 726) were dideoxy sequenced, as previously de-
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scribed (4). To detect polymorphisms in pfcrt and pfmdr1, multi-
plex ligase detection reaction-fluorescent microsphere assays were
performed, as previously described (19, 20).
We collected 53 isolates from patients with malaria from May
to July 2014. Giemsa-stained thin smears from all blood samples
demonstrated P. falciparum only, at parasitemias of 0.1% to
24.3%. We determined ex vivo IC50 data for 15 isolates. Values
ranged from 0.4 to 2.7 nM (geometric mean, 1.6 nM) for DHA
and 9.8 to 1,060 nM for chloroquine (Table 1).
As standard drug sensitivity assays have not identified artemis-
inin resistance in Asian isolates, we also assessed DHA suscepti-
bility using the ex vivo RSA (3). Ten isolates were lost to contam-
ination or failed to grow. For the remaining 43 isolates, assessed 72
h after culture initiation, most DHA-pulsed cultures contained
pyknotic forms, and only 3 of 43 demonstrated healthy-appearing
parasites, all with parasitemia that was 0.025%. Of the 3 positive
cultures, a single parasite was detected per 15,000 erythrocytes
in 2 cultures, and 3 parasites were detected in the third (RSA
survival rates, 0.7% to 1.9%). All 43 untreated control cultures
demonstrated increased parasitemia and healthy-appearing para-
sites over the course of the assay. Because of the challenges of
quantifying extremely low parasitemia, we assessed the viability of
14 DHA-pulsed cultures that did not demonstrate parasites after
72 h. These cultures were maintained for up to 30 days after initi-
ation of the experiment. Twelve of these cultures demonstrated
parasites, beginning 15 to 29 days after culture initiation; 2 cul-
tures remained negative at 30 days. Thus, we did not observe en-
hanced growth of DHA-pulsed parasites after 72 h in culture, ar-
guing against the presence of the artemisinin-resistant phenotype,
although most cultures survived the DHA pulse.
Sequencing the K13-propeller-encoding domains from the 53
isolates revealed two nonsynonymous mutations, S552C (mixed
with the wild-type sequence) and A578S, in propeller domains 2
and 4, respectively (Fig. 1). Ten isolates that grew in culture 15 to
29 days after the DHA pulse all had wild-type K13 sequences. Two
of these samples were from isolates that were positive by micros-
copy 72 h after the DHA pulse. Considering the putative drug
transporters encoded by pfcrt and pfmdr1, polymorphism preva-
lences were similar to those described recently from other regions
of Uganda, with an increased prevalence of wild-type sequences at
pfcrt K76, pfmdr1 N86, and pfmdr1 D1246 compared to older
studies (Fig. 1) (20, 21). Sensitivity to chloroquine correlated well
with the pfcrt K76T sequence, with IC50s that were 120 nM for all
mutant parasites, 16 nM for all wild-type parasites, and inter-
mediate for one mixed sample (Table 1).
Artemisinin resistance, with delayed clearance of parasites af-
ter treatment with artemisinin monotherapy or artemisinin com-
bination therapies (ACTs), is of great concern but not clearly pres-
ent in Africa, where clearance of parasites after treatment with
ACTs has generally been rapid (2, 13). Parasites from Southeast












86 184 1034 1024 1246
1 15.6 (14.6–16.6) 2.0 (1.7–2.4) 0 WTe K N F S N D
2 123 (84.4–180) 2.0 (1.5–2.6) 0 WT T N/Y Y/F S N Y
3 38.8 (23.5–64.3) 1.1 (1.0–1.3) 0 WT K/T N/Y Y/F S N D
4 11.2 (9.7–13) 1.4 (1.2–1.5) 0 WT K N F S N Y/D
5 260 (154–440) 2.3 (1.6–3.4) 0 WT T N Y S N Y
6 196 (127–300) 1.8 (1.5–2.0) 0 WT T N F S N D
7 9.8 (9.2–10.5) 1.3 (0.9–1.7) 0 WTf K N F S N D
8 155 (133–182) 2.3 (2.0–2.6) 0 WT T N Y/F S N Y
9 141 (86.7–228) 1.5 (1.2–1.9) 0 WT T N Y/F S N D
10 139 (116–166) 2.0 (1.8–2.2) 0.7 WT T N F S N D
11 1060 (733–1520) 2.2 (2.0–2.5) 0 WT T N Y S N D
12 222 (169–291) 1.6 (1.5–1.7) 0 A578Sg T N F S N D
13 204 (147–283) 2.7 (2.3–3.2) 0 WT T N Y/F S N D
14 240 (183–313) 0.47 (0.45–0.49) ND WT T N Y S N D
15 182 (144–231) 0.90 (0.81–0.93) ND WT T N/Y Y S N D
a Data are shown for isolates for which IC50 and K13 sequence data are available. WT, wild type; ND, no data collected.
b CQ, chloroquine; CI, confidence interval; the 95% CI describes precision of the IC50 determined from the curve fit. Ex vivo IC50 tests are single assays.
c Percentage of parasites in DHA-treated cultures relative to controls 72 h after initiation of a 6-h DHA pulse.
d aa, amino acid. Wild-type PfCRT is K76, and wild-type PfMDR1 is NYSND.
e Synonymous single nucleotide polymorphism (SNP) t1512c.
f Synonymous SNP c1434g.
g Reported from Tororo, Uganda (10), Democratic Republic of Congo (14), and Bangladesh (23).
FIG 1 Prevalences of wild-type, mixed, and mutant sequences at the indicated
positions.
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Asia with delayed clearance typically do not show decreased sen-
sitivity with standard in vitro assays but demonstrate decreased
sensitivity to a DHA pulse in the RSA (3) and have specific muta-
tions in K13-propeller-encoding domains (4). We screened fresh
P. falciparum isolates from Uganda for these artemisinin resis-
tance markers. Using the RSA, nearly all freshly isolated Ugandan
parasites had undetectable parasitemia 72 h after exposure to a
pulse of DHA. In contrast, DHA-treated Southeast Asian parasites
had measurable parasitemia at 72 h, with parasitemia greater in
those with delayed clearance in clinical trials and the presence of
K13-propeller gene polymorphisms (3). A small percentage of
Ugandan parasites had K13-propeller gene mutations, but these
were not the mutations previously associated with drug resistance.
Thus, our results suggest that artemisinin resistance is not yet a
problem in Uganda.
Recent evidence suggests spreading of artemisinin resistance
beyond the initial reports from Cambodia (1), with the delayed
clearance phenotype and K13 mutations detected in parts of Thai-
land, Vietnam, Myanmar, and southern China (2, 6, 22). Addi-
tional K13-propeller gene mutations have been identified from
other regions of Asia (23) and Africa (11-13, 15), but these have
not been among the 10 mutations linked with delayed clearance
in Southeast Asia (4, 22). The K13 mutations detected in our
study, S522C and A578S, have been found elsewhere in Africa and
in Bangladesh, but they were not associated with a resistance phe-
notype (14, 15, 23). Considering our ring-stage survival assay re-
sults in which 40 of 43 DHA-pulsed samples were smear-negative,
it appeared that those parasites were more susceptible to a DHA
pulse than even susceptible parasites from Southeast Asia (3).
With prolonged observation, most samples showed regrowth of
parasites, indicating that, although its effect was marked, the 6-h
DHA pulse generally did not kill all parasites.
Our results are reassuring concerning artemisinin resistance in
Uganda, but they must be considered together with results show-
ing important changes in P. falciparum in the country in recent
years. With adoption of artemether-lumefantrine as standard
therapy for malaria within the last decade, parasites have demon-
strated increasing prevalence of pfcrt and pfmdr1 alleles that me-
diate decreased lumefantrine sensitivity (20) and, in ex vivo assays,
decreasing sensitivity to lumefantrine (17). Thus, even without
the artemisinin resistance phenotype, changes in parasite drug
sensitivity may threaten the antimalarial efficacies of ACTs, in
particular artemether-lumefantrine, in Uganda.
Our study had some limitations. We studied a convenience
sample of isolates, and consideration of host factors that may have
impacted on parasite biology or genetics was not possible. The
total number of isolates studied was small, and we were able to
perform some assays only in subsets of these isolates. We also
could not determine how an elevated survival phenotype would
manifest in our ex vivo assay, since resistance-conferring K13 mu-
tations were not evident in our study. Further, identification of
unusual polymorphisms may have been difficult in samples with
high complexity of infection, as is common in Uganda. For these
reasons we may have missed uncommon resistance markers, but
our results nonetheless argue against significant artemisinin resis-
tance in Uganda at this time.
Taken together, results from our parasitological and molecular
assessments and from recent clinical trials suggest that artemisinin
resistance is not yet an important problem in Uganda. However,
the recent spread of resistance in Asia suggests that the introduc-
tion or de novo emergence of resistance in Africa, the major world
focus of P. falciparum malaria, is likely. Further, altered sensitivity
to artemisinin partner drugs already threatens the efficacy of
ACTs for the treatment of P. falciparum malaria in Africa (17, 20).
Thus, regular surveillance for markers of artemisinin resistance is
needed across Africa.
Nucleotide sequence accession numbers. Nucleotide se-
quence data are available in the GenBank database under acces-
sion numbers KR055739 to KR055804.
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